Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Raw Materials: 2023-2025

Historic Raw Materials for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to $1.0 million.

  • Phathom Pharmaceuticals' Raw Materials fell 50.02% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 50.02%. This contributed to the annual value of $1.7 million for FY2024, which is 208.20% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Raw Materials is $1.0 million, which was up 1.72% from $991,000 recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Raw Materials registered a high of $2.0 million during Q3 2024, and its lowest value of $111,000 during Q2 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Raw Materials value was $999,500 (recorded in 2025), while the average stood at $990,600.
  • Its Raw Materials has fluctuated over the past 5 years, first skyrocketed by 1,717.12% in 2024, then plummeted by 50.02% in 2025.
  • Phathom Pharmaceuticals' Raw Materials (Quarterly) stood at $561,000 in 2023, then skyrocketed by 208.20% to $1.7 million in 2024, then slumped by 50.02% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $991,000 for Q2 2025, and $1.4 million during Q1 2025.